New blood test aims to catch live prostate cancer cells

NCT ID NCT04581109

Terminated Diagnosis Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new blood test called EPIDROP that looks for live circulating tumor cells in men with metastatic prostate cancer. The test uses a special technique to isolate single cells and measure their activity. Researchers want to see if EPIDROP is as good as or better than the current standard test, CellSearch. The study involves 100 men with metastatic prostate cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EPIDROP blood test
What this could lead to: If successful, this could provide a more accurate and sensitive way to detect circulating tumor cells, helping guide treatment decisions for prostate cancer.
What could go wrong: This is an early-stage diagnostic study with 100 participants, so results may not be definitive or widely applicable. The new test may not prove better than the existing method.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma Neoplastic Cells, Circulating prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

University Center, Hospital

Nîmes, France
University Hospital Center

Montpellier, Occitanie, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.